6C4C

ICD-11 MMS 2026-01

Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]

Description

Disorders due to use of MDMA (methylene-dioxymethamphetamine) or related drugs, including MDA (methylene-dioxyamphetamine) are characterised by the pattern and consequences of MDMA or related drug use. MDMA is a common drug of abuse in many countries especially among young people. It is predominantly available in tablet form known as ‘ecstasy’. Pharmacologically, MDMA has stimulant and empathogenic properties and these encourage its use among young people for social and other interactions. Considering its wide prevalence in many countries and among many sub-groups of young people, MDMA and Related Drug Dependence and MDMA and Related Drug Withdrawal are comparatively uncommon. Substance-Induced Mental Disorders may arise from its use. Several analogues of MDMA exist, including MDA.

Excludes

  • QE11.6 – Hazardous use of MDMA or related drugs

Exclusions from above levels

  • QE62 – Uncomplicated bereavement
  • QE84 – Acute stress reaction

Child codes

  • 6C4C.0 – Episode of harmful use of MDMA or related drugs, including MDA
  • 6C4C.1 – Harmful pattern of use of MDMA or related drugs, including MDA
  • 6C4C.2 – MDMA or related drug dependence, including MDA
  • 6C4C.3 – MDMA or related drug intoxication, including MDA
  • 6C4C.4 – MDMA or related drug withdrawal, including MDA
  • 6C4C.5 – MDMA or related drug-induced delirium, including MDA
  • 6C4C.6 – MDMA or related drug-induced psychotic disorder, including MDA
  • 6C4C.7 – Certain specified MDMA or related drug-induced mental or behavioural disorders, including MDA
  • 6C4C.Y – Other specified disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
  • 6C4C.Z – Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA], unspecified

Sibling codes

  • 6C40 – Disorders due to use of alcohol
  • 6C41 – Disorders due to use of cannabis
  • 6C42 – Disorders due to use of synthetic cannabinoids
  • 6C43 – Disorders due to use of opioids
  • 6C44 – Disorders due to use of sedatives, hypnotics or anxiolytics
  • 6C45 – Disorders due to use of cocaine
  • 6C46 – Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone
  • 6C47 – Disorders due to use of synthetic cathinones
  • 6C48 – Disorders due to use of caffeine
  • 6C49 – Disorders due to use of hallucinogens
  • 6C4A – Disorders due to use of nicotine
  • 6C4B – Disorders due to use of volatile inhalants
  • 6C4D – Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)
  • 6C4E – Disorders due to use of other specified psychoactive substances, including medications
  • 6C4F – Disorders due to use of multiple specified psychoactive substances, including medications
  • 6C4G – Disorders due to use of unknown or unspecified psychoactive substances
  • 6C4H – Disorders due to use of non-psychoactive substances
  • 6C4Y – Other specified disorders due to substance use
  • 6C4Z – Disorders due to substance use, unspecified

Foundation entity

Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA] – http://id.who.int/icd/entity/1218193465

Allowed postcoordination axes

Part of: 06: Mental, behavioural or neurodevelopmental disorders